Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Paclitaxel. Found 59 abstracts

no pagination
Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol. 2017 Aug;40(4):393-8.   PMCID: PMC5026539
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):779-91.   PMCID: PMC5715461
Xu MJ, Chu C, Rubin S, Lin LL. Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma. Am J Clin Oncol. 2017 Dec;40(6):598-604.   PMCID: PMC4733581
Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. The New England journal of medicine. 2016 Feb 25;374(8):738-48.   PMCID: PMC5081077
Chan JK, Java JJ, Fuh K, Monk BJ, Kapp DS, Herzog T, Bell J, Young R. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials. Gynecol Oncol. 2016 Dec;143(3):490-5.   PMCID: PMC5728987
Chow LQ, Smith DC, Tan AR, Denlinger CS, Wang D, Shepard DR, Chaudhary A, Lin Y, Gao L. Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors. Cancer Chemother Pharmacol. 2016 Aug;78(2):433-41.   PMCID: PMC4965482
Burness ML, Obeid EI, Olopade OI. Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. Clin Breast Cancer. 2015 Apr;15(2):e155-8.
Rapoport N, Gupta R, Kim YS, O'Neill BE. Polymeric micelles and nanoemulsions as tumor-targeted drug carriers: Insight through intravital imaging. J Control Release. 2015 May 28;206:153-60.
Jacobs JD, Hopper-Borge EA. Carotid artery infusions for pharmacokinetic and pharmacodynamic analysis of taxanes in mice. Journal of visualized experiments : JoVE. 2014 Oct 27;92(92):e51917.   PMCID: 4353391
Langer CJ, Novello S, Park K, Krzakowski M, Karp DD, Mok T, Benner RJ, Scranton JR, Olszanski AJ, Jassem J. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2014 Jul;32(19):2059-66.   PMCID: Pmc4067944
Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clin Cancer Res. 2014 Jun;20(11):3023-32.   PMCID: Pmc4049169
Teijaro CN, Munagala S, Zhao S, Sirasani G, Kokkonda P, Malofeeva EV, Hopper-Borge E, Andrade RB. Synthesis and biological evaluation of pentacyclic strychnos alkaloids as selective modulators of the ABCC10 (MRP7) efflux pump. Journal of medicinal chemistry. 2014 Dec 26;57(24):10383-90.   PMCID: PMC4281106
Tu Y, Hershman DL, Bhalla K, Fiskus W, Pellegrino CM, Andreopoulou E, Makower D, Kalinsky K, Fehn K, Fineberg S, Negassa A, Montgomery LL, Wiechmann LS, Alpaugh RK, Huang M, Sparano JA. A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast Cancer Res Treat. 2014 Jul;146(1):145-52.
Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, Bycott P, Ingrosso A, Kim S, Williams JA, Chen C, Olszanski AJ, de Besi P, Schiller JH. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Ann Oncol. 2014 Jan;25(1):132-8.   PMCID: No NIH funds
Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009 Mar 20;27(9):1419-25.   PMCID: PMC 2668552
Borghaei H, Langer CJ, Millenson M, Ruth KJ, Litwin S, Tuttle H, Seldomridge JS, Rovito M, Mintzer D, Cohen R, Treat J. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol. 2008 Nov;3(11):1286-92.
Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol. 2008 May;19(5):977-83.
Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Lesniewski-Kmak K, Smakal M, Ciuleanu TE, Orlov SV, Dediu M, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW, Ross HJ. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jun;3(6):623-30.
McMeekin DS, Walker JL, Hartenbach EM, Bookman MA, Koh WJ. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008 Jan;112(1):134-41.
Morgan MA, Darcy KM, Rose PG, DeGeest K, Bookman MA, Aikins JK, Sill MW, Mannel RS, Allievi C, Egorin MJ, Gynecologic Oncology G. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol. 2008 Sep;110(3):329-35.   PMCID: PMC2577579
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Paclitaxel

Paclitaxel Female administration & dosage Middle Aged Antineoplastic Combined Chemotherapy Protocols therapeutic use Carboplatin drug therapy Aged Adult Disease-Free Survival pathology adverse effects metabolism Neoplasm Staging Male Ovarian Neoplasms Treatment Outcome mortality therapy Survival Rate 80 and over Aged Lung Neoplasms adverse effects Non-Small-Cell Lung Carcinoma Kaplan-Meier Estimate Drug Administration Schedule Bevacizumab Peritoneal Neoplasms Doxorubicin Intravenous Infusions Prognosis Neoplasm Drug Resistance Phytogenic Antineoplastic Agents Proportional Hazards Models pharmacokinetics Squamous Cell Carcinoma genetics Polyglutamic Acid dosage Retrospective Studies Cytoreduction Surgical Procedures derivatives administration & Chemoradiotherapy Cisplatin Cystic Neoplasms-Mucinous-and Serous Young Adult Antineoplastic Agents Glandular and Epithelial Neoplasms Cohort Studies chemically induced Adenocarcinoma Cyclophosphamide Clear Cell Adenocarcinoma Head and Neck Neoplasms secondary Monoclonal Antibodies-Humanized Endometrioid Carcinoma Fallopian Tube Neoplasms Local Neoplasm Recurrence Salvage Therapy Monoclonal Antibodies Ki-67 Antigen Maximum Tolerated Dose Intention to Treat Analysis epidemiology Survival Analysis Advanced endometrial cancer radiation therapy surgery Multivariate Analysis Drug Delivery Systems Optical Imaging Whole abdominal Breast Neoplasms Hydroxamic Acids Nanoparticle extravasation Taxoids Tumor Biomarkers Piperidines Peripheral Nervous System Diseases Animal Models FEASIBILITY Nude Mice Drug Interactions Cyclin-Dependent Kinase Inhibitor p21 chemotherapy Follow-Up Studies Intravital microscopy ras Proteins Intra-Arterial Infusions Multidrug Resistance-Associated Proteins Nanoparticles Imidazoles Phosphatidylinositol 3-Kinases Drug Carriers drug effects Feasibility Studies Epidermal Growth Factor Receptor Indazoles methods Nanodroplets CARCINOMA Radiotherapy HEK293 Cells Triple Negative Breast Neoplasms Polymers Hysterectomy Nanoparticle diffusion Antineoplastic Antibiotics Perfluorocarbon Quinazolines Drug delivery non-squamous Survival Fluorouracil ABDOMINOPELVIC IRRADIATION United States Neutropenia chemistry bevacizumab chemical synthesis Parenteral Infusions BRCA1 Genes Abdominal Neoplasms RADIOTHERAPY STAGE-III analogs & Adjuvant Chemotherapy Hematologic Diseases Heterozygote Quality of Life Microscopy physiology Multiple Drug Resistance ADVANCED CERVICAL-CANCER Molecular Targeted Therapy pharmacology non-small-cell lung cancer Epothilones Histone Deacetylases Adenosine Triphosphatases Biological Tumor Markers Tissue Array Analysis Signal Transduction TAXOL trends Mitogen-Activated Protein Kinase Kinases
Last updated on Friday, January 03, 2020